Since our inception in 2004, Creative Biolabs has become the leading expert in TCR and CAR-T&NK cell immune therapy development, as we offer the one-stop custom services and products that cover the entire new drug development pipeline. Our services and products have been used extensively by scientists all over the world to accelerate their life science research. Here, we present a collection of representative citations.
For your convenience, we have grouped these patents & articles into the following categories:
SECTION 1: CAR-T/CAR-NK Cell Development Services[Top]
Creative Biolabs offers high-quality custom service covering the entire CAR-T/CAR-NK therapy development process to best suit your technical, program and budget requirements which can greatly assist your research, preclinical investigation and clinical stage development.
The researchers demonstrated that targeted nanocarriers that deliver a combination of immune-modulatory agents can remove protumor cell populations and simultaneously stimulate antitumor effector cells. The anti-ROR1-28z CAR and the anti-EGFRvIII-28z CAR were custom-designed by Creative Biolabs.
The authors demonstrated that the combination of CD19 CAR-T cells and nivolumab was feasible and safe and mediated potent anti-lymphoma activity. Creative Biolabs helped transducing the T cells with a lentiviral vector containing a CAR with a CD3-zeta domain and a 4-1BB (CD137) domain.
SECTION 2: Products for CARs/TCRs Development [Top]
Creative Biolabs provides the most complete collection of products for CAR-T/TCR-T cell development, including but not limited to CAR/TCR vector products, CAR/TCR viral particles, transposon systems, immune cell products, and kits for T/NK cell culture & isolation, CAR construction & transfection, virus packaging, and CAR-T cell testing.
The authors provided proof of concept that allogeneic mesothelin-CAR NK-92MI cells with hybrid Sleeping Beauty and minicircle technologies provide increased engraftment and cytotoxicity in vitro with potential safety benefits when translated to the clinical arena. The pSB11 transposase vector and pDonR-SB transposon were both obtained from Creative Biolabs.
The authors demonstrated the feasibility of producing CAR-T cells in an academic context and can serve as a paradigm for similar institutions. The pCAR19, and LentiArt™ Virus Packaging Kit (containing LentiArt™ pHelp1, pHelp2, and pHelp3) were both obtained from Creative Biolabs.
For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE